Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 152Recruiting 49Unknown 40Terminated 38Active not recruiting 18Withdrawn 14Not yet recruiting 8Suspended 3No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Mesothelioma 4Solid Tumors 3Solid Tumor 3Neoplasms 3Mesothelioma, Malignant 3Unspecified Adult Solid Tumor, Protocol Specific 2Small Cell Lung Carcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Advanced Refractory Solid Tumors 2Uterine Cervical Neoplasms 1Solid Tumor, Childhood 1Psoriasis 1Prostatic Neoplasms 1Post-Lyme Disease Syndrome 1Parkinson Disease 1Obsessive-Compulsive Disorder 1Myasthenia Gravis 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Sclerosis, Chronic Progressive 1Multiple Sclerosis 1Migraine Disorders 1Malignant Solid Neoplasm 1Lyme Neuroborreliosis 1Lyme Disease 1Lung Neoplasms 1Irritable Bowel Syndrome 1Hypercholesterolemia 1Hodgkin Disease 1Hematopoietic and Lymphoid System Neoplasm 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Suspended × Mesothelioma, Malignant × Other solid neoplasm × Clear all
NCT05337735 2026-05-04

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

M.D. Anderson Cancer Center

Phase 2 Suspended
140 enrolled
EndocrineGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Hodgkin Disease, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05960773 2026-05-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Suspended
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT01627795 2018-04-18

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Oshadi Drug Administration

Phase 1/2 Suspended
17 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡